We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • My watchlists
  • Help
  • Contact us

Vaxcyte Inc (PCVX) USD0.0013

Sell:$26.09 Buy:$26.19 Change: $0.77 (3.04%)
NASDAQ:1.67%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$26.09
Buy:$26.19
Change: $0.77 (3.04%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$26.09
Buy:$26.19
Change: $0.77 (3.04%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Vaxcyte Inc. is a clinical-stage vaccine company focused on developing vaccines to protect humankind from the consequences of bacterial diseases. The Company’s pipeline includes pneumococcal conjugate vaccine (PCV), VAX-24, VAX-XP, VAX-A1 and VAX-PG. The Company’s PCV candidates is in development, targeting global pneumococcal vaccine market. The Company’s lead vaccine candidate, VAX-24, is a 24-valent, broad-spectrum investigational PCV being developed for the prevention of invasive pneumococcal disease (IPD) and pneumonia. The Company’s PCV candidate, VAX-XP, leverages its scalable and modular platform and builds on the technical proof-of-concept established by VAX-24. VAX-A1 is a novel conjugate vaccine candidate designed to prevent Group A Strep pervasive disease. VAX-PG is a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis and chronic oral inflammatory disease.

Contact details

Address:
825 INDUSTRIAL ROAD, STE. 300
SAN CARLOS
94070
United States
Telephone:
+1 (650) 8370111
Website:
https://vaxcyte.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PCVX
ISIN:
US92243G1085
Market cap:
$1.56 billion
Shares in issue:
59.32 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Andrew Guggenhime
    President, Chief Financial Officer
  • Grant Pickering
    Chief Executive Officer, Co-Founder, Director
  • Jeff Fairman
    Co-Founder, Vice President - Research
  • Jim Wassil
    Chief Operating Officer, Executive Vice President
  • Mikhail Eydelman
    Senior Vice President, General Counsel, Corporate Secretary
  • Paul Sauer
    Senior Vice President - Process Development and Manufacturing

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.